DiaMedica Therapeutics Inc. Stock Toronto S.E.
Equities
DMA
CA25253X2077
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 134M 98.08M |
---|---|---|---|---|---|
Net income 2024 * | -37M -27.04M | Net income 2025 * | -47M -34.35M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-3.12
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Therapeutics Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |